These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31354394)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptides for in vivo target-specific cancer imaging.
    Ferro-Flores G; Ramírez Fde M; Meléndez-Alafort L; Santos-Cuevas CL
    Mini Rev Med Chem; 2010 Jan; 10(1):87-97. PubMed ID: 20380643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging.
    Vandergaast R; Khongwichit S; Jiang H; DeGrado TR; Peng KW; Smith DR; Russell SJ; Suksanpaisan L
    Cancer Gene Ther; 2020 Apr; 27(3-4):179-188. PubMed ID: 30674994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic role of 99mTc-dual receptor targeted probe and targeted peptide bombesin (RGD-BBN) SPET/CT in the detection of malignant and benign breast tumors and axillary lymph nodes compared to ultrasound.
    Ji T; Sun Y; Chen B; Ji B; Gao S; Ma Q; Cheng G; Zhang H
    Hell J Nucl Med; 2015; 18(2):108-13. PubMed ID: 26187209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging Techniques in Pharmacological Precision Medicine.
    Freidel L; Li S; Choffart A; Kuebler L; Martins AF
    Handb Exp Pharmacol; 2023; 280():213-235. PubMed ID: 36907970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging requirements for personalized medicine: the oncologists point of view.
    Kruse V; Belle SV; Cocquyt V
    Curr Pharm Des; 2014; 20(14):2234-49. PubMed ID: 24025098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular imaging for personalized cancer care.
    Kircher MF; Hricak H; Larson SM
    Mol Oncol; 2012 Apr; 6(2):182-95. PubMed ID: 22469618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging cancer using single photon techniques.
    Buscombe JR; Bombardieri E
    Q J Nucl Med Mol Imaging; 2005 Jun; 49(2):121-31. PubMed ID: 16010250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).
    Rangasamy L; Geronimo BD; Ortín I; Coderch C; Zapico JM; Ramos A; de Pascual-Teresa B
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular imaging biomarkers for immune checkpoint inhibitor therapy.
    van de Donk PP; Kist de Ruijter L; Lub-de Hooge MN; Brouwers AH; van der Wekken AJ; Oosting SF; Fehrmann RS; de Groot DJA; de Vries EG
    Theranostics; 2020; 10(4):1708-1718. PubMed ID: 32042331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast (T1/T2) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis.
    Xue S; Zhang C; Yang Y; Zhang L; Cheng D; Zhang J; Shi H; Zhang Y
    J Biomed Nanotechnol; 2015 Jun; 11(6):1027-37. PubMed ID: 26353592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial. Molecular image-guided cancer treatment: moving towards personalized medicine--Part I.
    Liu Z
    Curr Pharm Biotechnol; 2013; 14(7):643. PubMed ID: 24476455
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
    Sheikhbahaei S; Mena E; Pattanayak P; Taghipour M; Solnes LB; Subramaniam RM
    PET Clin; 2017 Jan; 12(1):105-118. PubMed ID: 27863562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.
    Santhanam P; Solnes LB; Rowe SP
    Med Oncol; 2017 Oct; 34(12):189. PubMed ID: 29086115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of molecular imaging in modern drug development.
    Cunha L; Szigeti K; Mathé D; Metello LF
    Drug Discov Today; 2014 Jul; 19(7):936-48. PubMed ID: 24434047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular imaging in the framework of personalized cancer medicine.
    Belkić D; Belkić K
    Isr Med Assoc J; 2013 Nov; 15(11):665-72. PubMed ID: 24511645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular image-guided theranostic and personalized medicine 2014.
    Zhang H; Tian M; Carrio I; Civelek AC; Fujibayashi Y
    Biomed Res Int; 2015; 2015():258612. PubMed ID: 25883947
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe.
    Misri R; Meier D; Yung AC; Kozlowski P; Häfeli UO
    Nanomedicine; 2012 Aug; 8(6):1007-16. PubMed ID: 22100757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
    Basu S; Alavi A
    PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases.
    Palumbo B; Buresta T; Nuvoli S; Spanu A; Schillaci O; Fravolini ML; Palumbo I
    Int J Mol Sci; 2014 Jun; 15(6):9878-93. PubMed ID: 24897023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.